Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Our mission is to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Prof. Christophe Leclercq,
Cardiac resynchronization therapy (CRT) is recommended in patients with left ventricular systolic dysfunction, wide QRS and moderate to severe heart failure (NYHA class III and IV) despite optimal drug treatment. In these patients, CRT improves symptoms, quality of life and significantly decreases morbi-mortality. The effects of CRT in patients with mild heart failure are currently evaluated.
What can we expect with CRT in patients with mild heart failure? The results of the MIRACLE ICD II and the CONTAK-CD trials gave some indications: in these two trials no significant improvement in quality of life, symptoms or exercise tolerance. However, as well as observed in “conventional” CRT was associated with a significant left ventricular reverse remodeling, i.e. a significant reduction in left ventricular end-systolic and end-diastolic volumes and an increase in left ventricular ejection fraction. These effects of CRT on LV remodeling are currently evaluated in three on-going trials: the REVERSE trial; the MADIT CRT trial and the RAFT trial. The first results, those of the REVERSE trial, will be presented in 2008. However, the current guidelines, even the most recent guidelines don’t recommend so far CRT in NYHA class II patients.
353 - 355
The patient with mild heart failure - how to prevent disease progression?
© 2017 European Society of Cardiology. All rights reserved